Mass GLP-1 Prescribing Raises Safety Concerns as Use Becomes Mainstream

A class of medications that once lived quietly in diabetes clinics has swept into the cultural mainstream with a speed that outpaced the wisdom needed to guide it. GLP-1 drugs like Ozempic and Wegovy are reshaping how millions of people relate to their bodies and to medicine itself — but the infrastructure of careful monitoring, honest consent, and social acceptance has not arrived alongside the prescriptions. What unfolds now is a familiar human story: a powerful tool embraced before its full weight is understood.